AI-Driven Epigenetic Reprogramming: The First Human Trials of Cellular Rejuvenation

The Nobel Prize was awarded for cellular reprogramming in 2012. The first human trial began in 2026. The first patient was not treated for aging. She was treated for vision loss.

TIMELINE: Epigenetic Reprogramming — From Nobel to Clinic
─────────────────────────────────────────────────────────────
  2006 ──── 2012 ──── 2021 ──── 2023 ──── 2025 ──── 2026 ──── 2027
  🔬       🏆       🚀       🧪       💰       ◉ NOW    🔥 NEXT
  iPSC     Nobel    NewLimit  NewLimit  NewLimit  First     NewLimit
  discov.  Yamanaka  founded   $40M A    $130M B   human     clinical
                                                    dosed     trial

The insight driving this work is that aging involves reversible epigenetic changes rather than permanent genetic damage. By transiently expressing reprogramming factors, researchers can reset these epigenetic markers, effectively turning back cellular clocks while preserving specialized cell function. That balance between rejuvenation and identity is both the field's greatest promise and its primary technical challenge.

The Science — From Yamanaka to Partial Reprogramming

In 2006, Shinya Yamanaka discovered that four transcription factors (Oct4, Sox2, Klf4, and c-Myc) could reprogram adult cells back to an embryonic-like state. The discovery earned him the Nobel Prize in 2012 and opened a door that biology had assumed was locked: cellular identity is not permanent.

But complete reprogramming carried a risk. Cells pushed all the way to pluripotency could form tumors. The therapeutic version had to stop halfway, resetting the epigenetic clock without erasing the cell's identity.

That version is called partial epigenetic reprogramming. Instead of the full OSKM cocktail (Oct4, Sox2, Klf4, c-Myc), companies now use subsets, typically OSK without c-Myc, delivered transiently via gene therapy or mRNA. The cell becomes younger without becoming a stem cell.

"Reprogramming is like the AI of the bio world," Karl Pfleger, an investor backing Shift Bioscience, told MIT Technology Review in January 2026. "It's the thing everyone is funding."

The Clinical Frontier — First Human Data

On January 28, 2026, Life Biosciences announced that the FDA had cleared its Investigational New Drug application for ER-100, a gene therapy designed to partially reset the biological age of human cells using the PER (Partial Epigenetic Reprogramming) platform. It was the first time any cellular rejuvenation therapy had ever been authorized for testing in humans.

The company, co-founded by Harvard geneticist David Sinclair, enrolled patients with two eye diseases: glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The eye is an immunologically privileged site that allows for contained gene therapy delivery, and vision loss has a quality-of-life impact that makes a positive result immediately legible.

On June 9, 2026, Nature reported that the first patient had been dosed. "World-first: therapy to make cells young again trialled in a person," the headline read. The study (NCT07290244) is evaluating safety and tolerability, with initial efficacy data expected in Q4 2026.

If ER-100 shows a signal, even a safety signal with hints of efficacy, the implications cascade. Life Biosciences has already confirmed it is working on reprogramming approaches for the liver, heart, and brain. What begins as an eye therapy could become a platform for cellular rejuvenation across every organ system.

The Capital — NewLimit's $435M Bet

While Life Biosciences was working through FDA review, a younger company in South San Francisco was scaling faster than anyone expected. Co-founded in 2021 by Coinbase CEO Brian Armstrong, bioengineer Blake Byers, and computational biologist Jacob Kimmel, it raised $110 million at inception to build an AI-driven screening platform for epigenetic reprogramming.

Its approach differs from Life Biosciences. Instead of using Yamanaka factors, it developed a proprietary discovery system called Ambrosia, a machine learning platform that screens thousands of transcription factor combinations to find sets that restore youthful gene expression patterns. The system iterates through "lab in a loop" cycles: computational models predict candidates, experiments validate them, and the data retrains the AI.

In May 2025, the company closed a $130 million Series B led by Kleiner Perkins. CEO Jacob Kimmel told FierceBiotech at the time that a first human trial might not happen until 2030.

Then the data changed the timeline.

It discovered a prototype medicine that reversed cellular age markers in old human liver cells, years ahead of its own projected schedule. On June 2, 2026, the company announced a $435 million Series C led by Founders Fund, with participation from Thrive Capital, Greenoaks, Kleiner Perkins, and Eli Lilly Ventures. Post-money valuation: $3.1 billion. Total capital raised: over $610 million.

The first clinical trial in humans is now scheduled for 2027, targeting alcohol-related liver disease.

"Following breakthrough results, we're bringing longevity medicine to human trials," the company announced.

The Competitive Landscape

NewLimit and Life Biosciences are the two most advanced players in epigenetic reprogramming, but they operate alongside a cohort of heavily capitalized competitors.

Altos Labs, backed by Jeff Bezos and Yuri Milner with an estimated $3 billion in funding, pursues iPSC-based reprogramming across 14 disease indications. The company has appointed a new Chief Medical Officer, a sign it is moving toward clinical development, but has disclosed no timeline.

Retro Biosciences, funded with $180 million by Sam Altman, is pursuing autophagy and plasma-inspired therapies. The company was reportedly valued at $1.8 billion in a May 2026 funding round and is running a Phase 1 trial for its autophagy-promoting candidate RTR242 in Alzheimer's disease.

Turn Biotechnologies uses an mRNA-based ERA platform for dermatology applications, advancing toward an IND filing. Shift Bioscience in the UK applies machine learning to optimize reprogramming factor combinations for safety. Junevity, a UCSF spinout, is using AI-driven siRNA therapeutics for aging targets with roughly $10 million in seed funding.

What sets it apart is not just the speed of its transition from research to clinical development. It is that Eli Lilly Ventures joined the cap table. That matters: pharmaceutical capital now treats biological aging as a clinical category, not a wellness concept.

What This Changes

The convergence of AI-designed discovery platforms and clinical-stage epigenetic reprogramming creates something the longevity field has not had before: a falsifiable timeline. Life Biosciences' ER-100 will either show a signal or it will not. Its liver candidate will either pass safety or it will not. The answers are measurable, they are coming within 12 to 18 months, and they will determine whether cellular rejuvenation becomes a therapeutic category or joins the long list of interventions that worked in mice.

The market is already pricing in the optimistic case. The $5.5 billion that has flowed into reprogramming startups is concentrated in fewer than a dozen companies, most of which have no clinical data at all. That concentration carries risk: if ER-100 hits a safety problem or its preclinical results fail to replicate in humans, the correction will be sharp.

But if they work, if partial reprogramming safely resets the biological age of human cells, the category ceases to be a longevity experiment. It becomes the foundation of a new pharmaceutical industry with a multibillion-dollar addressable market and a mechanism that targets the root cause of age-related disease across every organ system.

In 2006, Yamanaka showed that cellular identity is reversible. In 2026, we learned that biological age may be too. The difference is that now there is a date attached.